NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Biotechnology · USD

Annovis Bio, Inc. (ANVS) Stock Analysis

Annovis Bio, Inc. (ANVS) is a Biotechnology stock listed on NYSE and quoted in US Dollar.

ANVS

$1.39

+$0.01 (+0.72%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANVS with… →

ANVS Key Statistics

As of Sep 4, 2026
Trading
Open
$1.40
Previous Close
$1.38
Day's Range
1.38–1.44
52-Week Range
1.32–5.50
Volume
1.53M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.24
Valuation
Market Cap
$59.22M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.76
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$28.85M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
42.61M
1-Year Return
−39.04%
Dividend and dates
Avg Volume
844.53K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ANVS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−59.83%
2025−31.21%
2024−73.10%
2023+39.24%
2022−23.61%
2021+133.16%
2020−21.38%

As of September 4, 2026.

ANVS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$28.85M—
2024$0.00−$24.59M—
2023$0.00−$56.20M—
2022$0.00−$25.33M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$29.70M−$28.85M—
2024$0.00—−$26.69M−$24.59M—
2023$0.00—−$45.04M−$56.20M—
2022$0.00—−$25.51M−$25.33M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ANVS Valuation vs Biotechnology Median

Median of 656 stocks
MetricANVSBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Annovis Bio, Inc. (ANVS) carries a market capitalisation of $59.22M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 7.

The 52-week range on file runs from $1.32 to $5.50. The most recent close on file for ANVS is $1.39, dated September 4, 2026. That is +$0.01 (+0.72%) against the previous close. The latest close sits 5.3% above that 52-week low.

Financial Health

In fiscal 2025, Annovis Bio, Inc. reported revenue of $0.00. The same year closed with a net loss of $28.85M. Profit margin runs at 0%. Trailing earnings per share are −1.76.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.24. Annualized volatility over the trailing 6 years is 125.78%. Over the trailing twelve months the price has returned −39.04%. Across 5 years the annualized return works out at −47.80%.

Growth & Income

The record shows no dividend for ANVS.

The strongest complete calendar year on file is 2021 at +133.16%; the weakest is 2024 at −73.10%. Of the 6 complete calendar years on file, 2 finished higher. So far in 2026 the price is −59.83%.

Peer Comparison

Annovis Bio, Inc. (ANVS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Annovis Bio, Inc. ANVS $59.22M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Annovis Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Visit website →